Trial Profile
An Open-label Pilot Study to Evaluate the Safety, Tolerability,Pharmacokinetics, Exploratory Efficacy and Pharmacodynamics of Oral Pazopanib Administered for 28 Days to Neovascular Age-relatedmacular Degeneration Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 29 Sep 2014 New trial record